A new relative tumor sizing method in epi-metaphyseal osteosarcoma

Seung Hyun Kim, Kyoo Ho Shin, Eun Hae Park, Yong Jin Cho, Byoung Kyu Park, Jinsuck Suh, Woo Ick Yang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The goal of this study was to develop a new method for determining tumor size to predict prognosis with high performance in osteosarcoma. Methods: This study was approved by the institutional review board. We retrospectively reviewed 41 magnetic resonance (MR) images at diagnosis and 57 MR images after neoadjuvant chemotherapy from 59 patients with non-metastatic, high-grade extremity osteosarcoma, who had undergone surgery between October 1994 and October 2009. Results: A new parameter of tumor axial ratio (TAR) was designed to normalize tumor size by dividing the absolute tumor axial size by the reference bone axial size (RBS) of the affected bone. RBS was defined using anatomical landmarks for each type of bone. Absolute tumor length (ATL), absolute tumor volume (ATV), and relative tumor volume (RTV) were comparatively analyzed. TAR was only significantly decreased after chemotherapy in the survival (P = 0.009) and metastasis-free (P = 0.018) group in the paired t-test. With the Kaplan-Meier method, significant differences in overall survival (log rank P = 0.004) and disease-free survival (Log Rank P = 0.009) were noted between decreased TAR after chemotherapy and increased TAR. After Cox regression analysis, TAR showed an odds ratios of 5.931 for survival (95% Confidence Interval [CI], 1.153-30.513) and 14.144 for metastasis (95% CI, 2.826-70.784), whereas ATL, ATV, and RTV showed no associations with these clinical variables. The AUC value of TAR was 0.713 (95% CI, 0.548 to 0.878) for survival and 0.759 (95% CI, 0.608 to 0.909) for metastasis. Conclusions: TAR is a novel sizing method with potential as a prognostic tool in osteosarcoma.

Original languageEnglish
Article number284
JournalBMC cancer
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 Apr 15

Fingerprint

Osteosarcoma
Neoplasms
Tumor Burden
Confidence Intervals
Bone and Bones
Survival
Neoplasm Metastasis
Drug Therapy
Magnetic Resonance Spectroscopy
Research Ethics Committees
Disease-Free Survival
Area Under Curve
Extremities
Odds Ratio
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Kim, S. H., Shin, K. H., Park, E. H., Cho, Y. J., Park, B. K., Suh, J., & Yang, W. I. (2015). A new relative tumor sizing method in epi-metaphyseal osteosarcoma. BMC cancer, 15(1), [284]. https://doi.org/10.1186/s12885-015-1129-9
Kim, Seung Hyun ; Shin, Kyoo Ho ; Park, Eun Hae ; Cho, Yong Jin ; Park, Byoung Kyu ; Suh, Jinsuck ; Yang, Woo Ick. / A new relative tumor sizing method in epi-metaphyseal osteosarcoma. In: BMC cancer. 2015 ; Vol. 15, No. 1.
@article{add89268e6344a32ad7c1cc09fb77c27,
title = "A new relative tumor sizing method in epi-metaphyseal osteosarcoma",
abstract = "Background: The goal of this study was to develop a new method for determining tumor size to predict prognosis with high performance in osteosarcoma. Methods: This study was approved by the institutional review board. We retrospectively reviewed 41 magnetic resonance (MR) images at diagnosis and 57 MR images after neoadjuvant chemotherapy from 59 patients with non-metastatic, high-grade extremity osteosarcoma, who had undergone surgery between October 1994 and October 2009. Results: A new parameter of tumor axial ratio (TAR) was designed to normalize tumor size by dividing the absolute tumor axial size by the reference bone axial size (RBS) of the affected bone. RBS was defined using anatomical landmarks for each type of bone. Absolute tumor length (ATL), absolute tumor volume (ATV), and relative tumor volume (RTV) were comparatively analyzed. TAR was only significantly decreased after chemotherapy in the survival (P = 0.009) and metastasis-free (P = 0.018) group in the paired t-test. With the Kaplan-Meier method, significant differences in overall survival (log rank P = 0.004) and disease-free survival (Log Rank P = 0.009) were noted between decreased TAR after chemotherapy and increased TAR. After Cox regression analysis, TAR showed an odds ratios of 5.931 for survival (95{\%} Confidence Interval [CI], 1.153-30.513) and 14.144 for metastasis (95{\%} CI, 2.826-70.784), whereas ATL, ATV, and RTV showed no associations with these clinical variables. The AUC value of TAR was 0.713 (95{\%} CI, 0.548 to 0.878) for survival and 0.759 (95{\%} CI, 0.608 to 0.909) for metastasis. Conclusions: TAR is a novel sizing method with potential as a prognostic tool in osteosarcoma.",
author = "Kim, {Seung Hyun} and Shin, {Kyoo Ho} and Park, {Eun Hae} and Cho, {Yong Jin} and Park, {Byoung Kyu} and Jinsuck Suh and Yang, {Woo Ick}",
year = "2015",
month = "4",
day = "15",
doi = "10.1186/s12885-015-1129-9",
language = "English",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Kim, SH, Shin, KH, Park, EH, Cho, YJ, Park, BK, Suh, J & Yang, WI 2015, 'A new relative tumor sizing method in epi-metaphyseal osteosarcoma', BMC cancer, vol. 15, no. 1, 284. https://doi.org/10.1186/s12885-015-1129-9

A new relative tumor sizing method in epi-metaphyseal osteosarcoma. / Kim, Seung Hyun; Shin, Kyoo Ho; Park, Eun Hae; Cho, Yong Jin; Park, Byoung Kyu; Suh, Jinsuck; Yang, Woo Ick.

In: BMC cancer, Vol. 15, No. 1, 284, 15.04.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A new relative tumor sizing method in epi-metaphyseal osteosarcoma

AU - Kim, Seung Hyun

AU - Shin, Kyoo Ho

AU - Park, Eun Hae

AU - Cho, Yong Jin

AU - Park, Byoung Kyu

AU - Suh, Jinsuck

AU - Yang, Woo Ick

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Background: The goal of this study was to develop a new method for determining tumor size to predict prognosis with high performance in osteosarcoma. Methods: This study was approved by the institutional review board. We retrospectively reviewed 41 magnetic resonance (MR) images at diagnosis and 57 MR images after neoadjuvant chemotherapy from 59 patients with non-metastatic, high-grade extremity osteosarcoma, who had undergone surgery between October 1994 and October 2009. Results: A new parameter of tumor axial ratio (TAR) was designed to normalize tumor size by dividing the absolute tumor axial size by the reference bone axial size (RBS) of the affected bone. RBS was defined using anatomical landmarks for each type of bone. Absolute tumor length (ATL), absolute tumor volume (ATV), and relative tumor volume (RTV) were comparatively analyzed. TAR was only significantly decreased after chemotherapy in the survival (P = 0.009) and metastasis-free (P = 0.018) group in the paired t-test. With the Kaplan-Meier method, significant differences in overall survival (log rank P = 0.004) and disease-free survival (Log Rank P = 0.009) were noted between decreased TAR after chemotherapy and increased TAR. After Cox regression analysis, TAR showed an odds ratios of 5.931 for survival (95% Confidence Interval [CI], 1.153-30.513) and 14.144 for metastasis (95% CI, 2.826-70.784), whereas ATL, ATV, and RTV showed no associations with these clinical variables. The AUC value of TAR was 0.713 (95% CI, 0.548 to 0.878) for survival and 0.759 (95% CI, 0.608 to 0.909) for metastasis. Conclusions: TAR is a novel sizing method with potential as a prognostic tool in osteosarcoma.

AB - Background: The goal of this study was to develop a new method for determining tumor size to predict prognosis with high performance in osteosarcoma. Methods: This study was approved by the institutional review board. We retrospectively reviewed 41 magnetic resonance (MR) images at diagnosis and 57 MR images after neoadjuvant chemotherapy from 59 patients with non-metastatic, high-grade extremity osteosarcoma, who had undergone surgery between October 1994 and October 2009. Results: A new parameter of tumor axial ratio (TAR) was designed to normalize tumor size by dividing the absolute tumor axial size by the reference bone axial size (RBS) of the affected bone. RBS was defined using anatomical landmarks for each type of bone. Absolute tumor length (ATL), absolute tumor volume (ATV), and relative tumor volume (RTV) were comparatively analyzed. TAR was only significantly decreased after chemotherapy in the survival (P = 0.009) and metastasis-free (P = 0.018) group in the paired t-test. With the Kaplan-Meier method, significant differences in overall survival (log rank P = 0.004) and disease-free survival (Log Rank P = 0.009) were noted between decreased TAR after chemotherapy and increased TAR. After Cox regression analysis, TAR showed an odds ratios of 5.931 for survival (95% Confidence Interval [CI], 1.153-30.513) and 14.144 for metastasis (95% CI, 2.826-70.784), whereas ATL, ATV, and RTV showed no associations with these clinical variables. The AUC value of TAR was 0.713 (95% CI, 0.548 to 0.878) for survival and 0.759 (95% CI, 0.608 to 0.909) for metastasis. Conclusions: TAR is a novel sizing method with potential as a prognostic tool in osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84928580661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928580661&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1129-9

DO - 10.1186/s12885-015-1129-9

M3 - Article

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 284

ER -